DMAC - CIK 0001401040
DiaMedica Therapeutics Inc. trades as DMAC. This page tracks DiaMedica Therapeutics Inc. through 414 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-21 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-01 |
| Proxy materials | DEFA14A | 2026-04-01 |
| Proxy statement | DEF 14A | 2026-04-01 |
| Major company event | 8-K | 2026-03-31 |
| Annual report | 10-K | 2026-03-30 |
The largest companies sharing DiaMedica Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
In its latest fiscal year DiaMedica Therapeutics Inc. reported a net loss of $32.77M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.